Gilead to Pay Merck $2.5B in Record Patent Ruling Over Hep C Therapies
Gilead will have to pay Merck $2.5 billion for infringing a patent that covers the active ingredient of its blockbuster hepatitis C drugs, Salvadi and Harvoni, in the country’s largest ever judgment for an infringement.
Source: Generic Line